ooking to end weeks of drama over an accounting scandal, Alexion Pharmaceuticals disclosed that senior management pressured employees to convince customers to order its key medicine in order to meet financial targets. The drug maker also sought to reassure Wall Street that the financial impact was limited, but some analysts called for more transparency and suggested the episode is a cautionary tale for the pharmaceutical industry.

The admission, which was contained in a regulatory filing made late Wednesday, followed an extraordinary episode that began in November, when an unnamed employee charged the drug maker engaged in fraud to hawk the Soliris rare disease treatment. The medicine generated $2.6 billion in revenue last year and currently accounts for more than 90 percent of company sales.

Unlock this article by subscribing to STAT Plus today. Try it FREE for 30 days and cancel anytime!


What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy